(ADPT)
NMS – Real vaqt narxi. Valyuta: USD
12.41
-1.55 (-11.10%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
12.65
+0.24 (1.93%)
Bozordan keyin: Mar 27, 2026, 7:49 PM EDT

NMS – Real vaqt narxi. Valyuta: USD
12.41
-1.55 (-11.10%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
12.65
+0.24 (1.93%)
Bozordan keyin: Mar 27, 2026, 7:49 PM EDT
Adaptive Biotechnologies Corporation, tijorat bosqichidagi kompaniya, turli kasalliklarni tashxislash va davolash uchun immunitet tibbiyoti platformasini ishlab chiqadi. Kompaniya immunitet tizimini tushunish uchun klinik immunomika ma'lumotlarini yaratish uchun patentlangan kimyo, hisoblash biologiyasi va mashinani o'rganish to'plamini birlashtirgan immunosekvenlash platformasini taklif etadi. U bemorning davolanish paytida va undan keyin uning tanasida mavjud bo'lgan saraton hujayralari sonini aniqlaydigan va kuzatadigan clonoSEQ diagnostika testini taqdim etadi, bu Minimal Qoldiq Kasallik (MRD) deb nomlanadi. Kompaniya hayot haqidagi fanlar tadqiqotlari, klinik diagnostika va dori-darmonlarni kashf qilish dasturlari uchun mahsulot va xizmatlarni taklif etadi. Kompaniya ilgari Adaptive TCR Corporation nomi bilan tanilgan va 2011 yil dekabr oyida Adaptive Biotechnologies Corporation nomini o'zgartirgan. Adaptive Biotechnologies Corporation 2009 yilda ro'yxatga olingan va Sietl, Vashingtonda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Harlan S. Robins Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Sharon Benzeno Ph.D. | Chief Commercial Officer of Immune Medicine |
| Mr. Chad M. Robins M.B.A. | Co-Founder, CEO & Chairman |
| Mr. Christopher Carlson Ph.D. | Founder |
| Mr. Francis T. Lo | Chief People Officer |
| Mr. Kyle Piskel | VP, CFO & Principal Accounting Officer |
| Ms. Clarice McCauley | Interim General Counsel, Corporate Secretary, VP & Chief Compliance Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-12 | 8-K | d29941d8k.htm |
| 2025-12-30 | 8-K | d81101d8k.htm |
| 2025-11-05 | 8-K | adpt-20251105.htm |
| 2025-08-18 | 8-K | d59058d8k.htm |
| 2025-08-05 | 10-Q | adpt-20250630.htm |
| 2025-06-12 | 8-K | d98087d8k.htm |
| 2025-05-01 | 8-K | adpt-20250501.htm |
| 2025-04-29 | DEFA14A | d946762ddefa14a.htm |
| 2025-03-03 | 10-K | adpt-20241231.htm |
| 2025-02-11 | 8-K | adpt-20250211.htm |
| Ms. Julie Rubinstein |
| President & COO |
| Ms. Karina Calzadilla | Vice President of Investor Relations |
| Ms. Susan Bobulsky | Chief Commercial Officer of MRD |